Metronidazole Baxter

Metronidazole, the active ingredient in Metronidazole Baxter, is a nitroimidazole antibiotic presented as a sterile solution for intravenous use. It treats anaerobic bacterial infections and related conditions in adult patients. GNH USA supplies Metronidazole Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is indicated for a range of anaerobic and protozoal infections. - Anaerobic bacterial infections: eradicates mixed anaerobic flora, reducing infection severity. - Bacterial vaginosis: restores normal vaginal flora by targeting Gardnerella species. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile strains in moderate disease. - Amoebiasis: destroys Entamoeba histolytica trophozoites, aiding resolution of intestinal lesions.

Metronidazole may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Metallic taste: transient alteration of oral sensation. - Headache: occasional dull or throbbing pain. - Diarrhoea: loose stools, often self‑limiting.

Serious or Rare Side Effects: - Peripheral neuropathy: tingling or numbness in extremities. - Seizures: rare central nervous system events. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or jaundice.

Metronidazole should be used with attention to patient history and clinical setting. - Renal impairment: adjust therapy if severe kidney dysfunction is present. - Hepatic disease: monitor liver function tests during prolonged treatment. - Alcohol consumption: advise patients to avoid alcohol due to disulfiram‑like reaction. - Pregnancy: use only if benefits outweigh potential risks, as safety data are limited. - Lactation: consider infant exposure through breast milk before prescribing. Store below 25°C: keep in original container, protect from light and moisture.

Metronidazole can affect the activity of several co‑administered drugs.

Major Interactions (Avoid): - Disulfiram: may cause severe flushing, tachycardia, and hypotension. - Warfarin: increased anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Lithium: potential for increased lithium levels and toxicity. - Cimetidine: may raise metronidazole plasma concentrations. - Phenytoin: possible reduction in phenytoin levels, requiring dose adjustment.